Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05883644 · ClinicalTrials.gov registry record · Phase 3
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
A Phase 3 study of Advanced Hepatocellular Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 111
- Enrollment target
- 20
- Study locations
NCT05883644: Active Phase 3 study of Advanced Hepatocellular Carcinoma, sponsored by AstraZeneca.
NCT05883644 is a Phase 3 study of Advanced Hepatocellular Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 111 participants, above the 81-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05883644, a Phase 3 study of Advanced Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 111 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
Primary Outcome
PRAE is defined as an AE which has been assessed by the investigator to be possibly related to IMP.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
Study Locations (20)
Other
- Research Site - Bobigny
- Research Site - Clichy
- Research Site - Créteil
- Research Site - Marseille
- Research Site - Rennes
- Research Site - Berlin
- Research Site - Cologne
- Research Site - Frankfurt
- Research Site - Lübeck
- Research Site - Hong Kong
- Research Site - Shatin
- Research Site - Milan
- Research Site - Naples
- Research Site - Padua
- Research Site - Pisa
- Research Site - Rozzano
- Research Site - Turin
California
- Research Site - La Jolla
Louisiana
- Research Site - Shreveport
Michigan
- Research Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
What the registry record for NCT05883644 still lists
NCT05883644 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, above the 81-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (37% higher).
The record links to 1 condition, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT05883644 names 20 study sites across 4 states, led by Other, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05883644 about?
NCT05883644 is a clinical study titled "Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)". This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
What is the current status of trial NCT05883644?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 2023-06-27. Estimated completion is 2026-09-30.
What conditions does trial NCT05883644 study?
This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05883644?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT05883644?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05883644 being conducted?
This trial has 20 study locations across California, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05883644's enrollment target sits among peer trials
111 6th of 16 higher than 11 of 16 other Advanced Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RECRUITING · Phase 3
-
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RECRUITING · Phase 1
-
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
RECRUITING · Phase 2
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
Ligufalimab and Cadonilimab in Advanced Liver Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI